Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives $118.90 Consensus Target Price from Analysts

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) have earned an average rating of “Moderate Buy” from the twenty-two analysts that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, twenty have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $118.90.

A number of equities research analysts have issued reports on the stock. B. Riley Financial increased their target price on shares of Kymera Therapeutics from $80.00 to $117.00 and gave the stock a “buy” rating in a report on Monday, December 22nd. Piper Sandler boosted their price target on shares of Kymera Therapeutics from $125.00 to $140.00 and gave the stock an “overweight” rating in a research note on Thursday, February 26th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kymera Therapeutics in a research note on Thursday, January 22nd. Truist Financial lifted their target price on Kymera Therapeutics from $80.00 to $116.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. Finally, Morgan Stanley reissued an “overweight” rating and set a $123.00 target price on shares of Kymera Therapeutics in a research note on Thursday, February 26th.

Insiders Place Their Bets

In other news, CFO Bruce N. Jacobs sold 7,576 shares of the business’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $88.93, for a total transaction of $673,733.68. Following the completion of the transaction, the chief financial officer directly owned 237,483 shares of the company’s stock, valued at approximately $21,119,363.19. The trade was a 3.09% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Jared Gollob sold 5,613 shares of the stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $88.93, for a total transaction of $499,164.09. Following the completion of the sale, the insider directly owned 122,029 shares in the company, valued at approximately $10,852,038.97. This represents a 4.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 312,538 shares of company stock worth $26,145,679. Corporate insiders own 16.01% of the company’s stock.

Hedge Funds Weigh In On Kymera Therapeutics

Several large investors have recently bought and sold shares of KYMR. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Kymera Therapeutics by 6.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,793 shares of the company’s stock worth $849,000 after acquiring an additional 1,833 shares in the last quarter. Millennium Management LLC boosted its stake in Kymera Therapeutics by 340.4% in the first quarter. Millennium Management LLC now owns 510,480 shares of the company’s stock valued at $13,972,000 after acquiring an additional 394,562 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Kymera Therapeutics by 121.5% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 896,404 shares of the company’s stock worth $24,535,000 after purchasing an additional 491,737 shares during the last quarter. PNC Financial Services Group Inc. increased its position in shares of Kymera Therapeutics by 506.6% during the second quarter. PNC Financial Services Group Inc. now owns 922 shares of the company’s stock worth $40,000 after purchasing an additional 770 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Kymera Therapeutics by 5.2% during the second quarter. Geode Capital Management LLC now owns 1,193,112 shares of the company’s stock worth $52,075,000 after purchasing an additional 59,347 shares in the last quarter.

Kymera Therapeutics Price Performance

NASDAQ KYMR opened at $78.16 on Tuesday. The company has a market cap of $6.38 billion, a P/E ratio of -21.24 and a beta of 2.20. The stock has a 50-day moving average of $80.23 and a two-hundred day moving average of $70.86. Kymera Therapeutics has a 1-year low of $19.44 and a 1-year high of $103.00.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings results on Thursday, February 26th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.77) by ($0.20). The business had revenue of $2.87 million for the quarter, compared to analyst estimates of $14.80 million. Kymera Therapeutics had a negative return on equity of 28.71% and a negative net margin of 794.04%.The firm’s revenue for the quarter was down 60.8% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.88) EPS. On average, analysts anticipate that Kymera Therapeutics will post -2.79 EPS for the current fiscal year.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.